A variety of studies suggest that the FHIT gene, which encompasses the fragile site at 3p14.2, is a candidate tumor suppressor gene in several forms of human cancer. To determine whether the FHIT gene is altered in prostate carcinomas, we examined 15 prostate tumors, four normal prostate tissue specimens and RNA from a pool of 62 normal human prostate tissues (Clontech) for the integrity of FHIT transcripts, using a robust singlestage PCR and a nested PCR method. In each case a major FHIT-speci®c full-length product was observed. Additional aberrantly sized products, which were more numerous in the nested PCR strategy, were present at a far lower level than the full-length transcripts in 14 of 15 tumors, three of four normal human prostate tissues and in the pooled normal prostate RNA. Sequence analysis revealed that these aberrant products corresponded to alternatively spliced FHIT transcripts, which were neither more numerous nor more prominent in the tumors than in the normal prostate specimens. Deletion at the FHIT locus was also evaluated by using three intragenic polymorphic markers (D13S1481, D3S1300, and D3S1234). Allelic loss was observed in two tumors, but these genomic alterations did not correspond to the aberrant FHIT transcripts. DNA analysis, furthermore, suggested that the tumor heterogeneity was not a likely explanation for presence of normal and alternatively spliced FHIT transcripts in the prostate tumors. In conclusion, we detected neither frequent loss of heterozygosity nor tumor speci®c transcripts of the FHIT gene in human prostate cancer.
Introduction
Prostate cancer is one of the most common malignancies among men in western countries (Parker et al., 1997) . Little is known of the acquired genetic changes that drive these tumors through the various stages of carcinogenesis. The most consistent genetic alterations in adenocarcinoma of the prostate are loss of heterozygosity (LOH) involving chromosome arms 7q, 8p, 10q, 13q, 16q, 17q and 18q, pointing to the presence of tumor suppressor genes (TSGs) in these deleted regions and their involvement in prostate carcinogenesis (Zenklusen et al., 1994; Bova et al., 1993; Ittman, 1996; Cooney et al., 1996; Carter et al., 1990; Gao et al., 1995; Latil et al., 1994) . The demonstration of LOH in certain chromosomes has potentially implicated previously identi®ed TSGs, incuding CDH1 on 16q (Umbas et al., 1992) , and DCC on 18q (Gao et al., 1993) , even though the precise role of these TSGs in prostate cancer is controversial. Nevertheless, inactivation of TSGs has been shown to play an important role in the development of a variety of human cancers, and the search is underway for other TSGs involved in prostate cancer. Although a variety of studies in various cancers have suggested that tumor suppressor loci on chromosome 3p play an important role in human neoplasia, this chromosome arm has rarely been investigated in prostate cancer; the few relevant studies have focused on the VHL locus at 3p25 (Cunningham et al., 1996; Dahiya et al., 1997) . Among the chromosome 3p regions thought to harbor tumor suppressor loci, chromosome 3p14.2 has recently been found to be prominent. Ohta et al. (1996) , using a positional cloning approach, identi®ed a novel gene in this region, which they named FHIT (fragile histidine triad gene) for its homology with the histidine triad gene family. FHIT which encompasses approximately 1 Mb of human genomic DNA, including the FRA3B common fragile region, encodes a typical dinucleoside 5',5''-P1, P3-triphosphate (Ap3A) hydrolase (Barnes et al., 1996) . In addition to its disruption in a kindred with a reciprocal t(3;8) chromosomal translocation, abnormal transcripts containing deletions of one or more coding exons, together with homozygous deletion of the region containing the gene and genomic DNA rearrangements have been found in many established cancer cell lines and solid tumors Mao et al., 1996; Negrini et al., 1996; Panagopoulos et al., 1996; Sozzi et al., 1996a,b; Thiagalingam et al., 1996; Virgilio et al., 1996; Yanagisawa et al., 1996; Druck et al., 1997; Fong et al., 1997; Hayashi et al., 1997; Hendricks et al., 1997; Luan et al., 1997) . These results make FHIT a candidate TSG for several human neoplasms.
With the aim of elucidating the role of FHIT in prostate tumorigenesis, we examined 15 malignant prostate tumors for LOH status at 3p14.2, and the transcription pattern of the FHIT gene. To investigate the molecular basis of the potential involvement of the FHIT gene, we compared tumor DNAs and autologous normal DNAs, by using three polymorphic markers withing the gene. After reverse transcription (RT), we examined the entire cDNA sequence of the gene (exon 1 ± 10) using both a robust single-stage PCR method (Thiagalingam et al., 1996) and a nested PCR assay .
Results

FHIT transcripts in primary prostate tumors
Single-stage PCR yielded a FHIT-speci®c product of the full length (756 bp) in each sample. In addition, seven tumors, two normal specimens and the pool of normal RNA yielded a faint band about 70 bp shorter than the full-length product. Sequence analysis of this 687-bp product revealed a loss of exon 8 in all ten cases. A 703-bp fragment generated by the loss of exon 3 was also observed in four tumors and one normal prostate sample. Faint bands of smaller size were also seen in one normal prostate sample (391 bp, N111) and in one tumor (490 bp, T71). The 391-bp product was generated by the fusion of exons 4 and 9, and the 490-bp transcript exhibited a loss of exons 3 ± 5.
Nested PCR yielded a FHIT-speci®c product of the full-length (683 bp), in each sample. In addition, aberrantly sized products were observed in most of the samples; indeed only one normal prostate specimen (N88) and one tumor (T69) yielded a single major FHIT-speci®c full-length product. Aberrant bands observed in single-stage PCR were present in nested PCR in the corresponding samples but novel aberrant bands were also seen after nested PCR. When another independent assay (repeat RT, and ®rst-round PCR) was performed, a major FHIT-speci®c full-length product was observed in each sample, but the size of the smaller band occasionally seen sometimes varied from one experiment to another.
Abnormally sized transcripts were sequenced and were found to lack various regions between exons 2 and 9 both in normal and tumor tissues. The fusion junctions coincided with splice sites in all abnormal transcripts. The level of spliced FHIT variants was always below 1% and 10% of the FHIT-speci®c fulllength product in single-stage and nested PCR, respectively. The alternatively spliced FHIT transcripts were detected due to the sensitive Applied Biosystems model 373A DNA sequencing system; indeed, most of them were not observed on agarose gel (Figure 2a and b) .
To con®rm the presence of spliced FHIT variants, single-stage PCR was carried out using primer pairs 182U/864L, 195U/864L and 109U/726L, which revealed FHIT variants generated by the fusion of exons 2 and 4, 2 and 7, and 7 and 9, respectively. A single band of variable intensity, corresponding to the expected spliced FHIT transcripts (630, 258 and 549 bp, respectively), was observed in 14 of the 15 tumors, three of the four normal prostate samples, and Nested PCR was performed using the primer pair 109U/864L for the ®rst round of PCR. The ampli®cation products were then subjected to a second round of PCR using the inner primers 155U and 837L in exons 2 and 10. In addition to the major band of 683 bp, faint PCR products of smaller size appeared in some samples. M, lane containing commercial molecular weight marker (éX174 DNA digested with HaeIII). Blank, control run in which reverse transcriptase was omitted in the pool of normal prostate RNA. The results matched those obtained by means of nested PCR: all FHIT-speci®c variants observed in a given specimen by nested PCR were found using the appropriate primer pair. N88 and T69 were the only specimens not to yield a signal with primer pairs 182U/864L, 195U/864L and 109U/726L.
Analysis of genomic DNA from prostate carcinomas
To investigate the molecular basis of the observed abnormalities in FHIT mRNA, we analysed the 15 prostate tumor DNAs and autologous normal DNA, using the polymorphic markers D13S1481, D3S1300, and D3S1234, which lie within the FHIT gene. Fourteen of the 15 prostate tumors were informative for at least two microsatellite markers, whereas the last (T60) was only heterozygous for the D3S1481 locus. Appepic Imbalance (AI) on at least one locus was found in two (T60 and T62) of the 15 tumor DNAs (13%). Results obtained by means of comparitive multiplex PCR suggested that the AI in these two tumors corresponded to LOH. T60 was deleted for D3S1481 and was homozygous for D3S1300 and D3S1234; T62 exhibited LOH at D3S1481 and D3S1234, and was homozygous for D3S1300.
Discussion
To study abnormalities in FHIT transcripts, we reverse transcribed mRNA and ampli®ed the cDNAs by using both a robust single-stage PCR method, and a nested PCR assay. In each of the 20 cases (15 prostate tumors, four normal prostate tissue specimens and total RNA from a pool of 62 normal human prostate tissues) a major FHIT-speci®c full-length product, containing the complete FHIT coding region, was observed. These results matched those obtained on colorectal and esophageal cancers (Thiagalingam et al., 1996; Zou et al., 1997) .
Additional bands of smaller size, representing alternatively spliced transcripts, were also seen.
All the aberrant bands obtained in single-stage PCR were also found in nested PCR in the corresponding sample, but some additonal bands appeared in nested PCR. The discrepancies between the two PCR strategies may be because the nested PCR overexpressed the shorter PCR products, as suggested by the observation of a major full-length FHIT band accompanied by a complex pattern of abnormal transcripts when we used robust nested PCR (two consecutive rounds of 35 cycles) (data not shown). Because FHIT variants are present at very low level, nested RT ± PCR is often necessary to detect them. However, when two independent assays starting with dierent cDNAs generated from a same RNA sample were performed, the size of the aberrant bands was not always identical in the two experiments. The phenomenon have been observed in another study , and might be due to the yield of the reverse transcription. Alternatively, spliced transcripts are present at a very lower level, and thus a robust ampli®cation may strongly favor ampli®cation of one among the dierent FHIT variants in accordance with the RT-yield.
Sequence analysis of the abnormally sized transcripts revealed a lack of various regions between exons 2 and 9 both in normal prostate tissues and tumors. The use of primer pairs encompassing the entire cDNA sequence of full-length FHIT allowed us to determine that the three most frequent spliced FHIT variants were FHIT-speci®c transcripts which had lost exon 3, exon 8, and exons 3 ± 6 (Figure 1b) . To con®rm the presence of these RNA splice variants, we analysed all the samples using primer pairs 182U/864L, 195U/864L and 109U/726L (see experimental procedures). The 630, 258 and 549-bp PCR products, corresponding to the transcripts generated by the fusion of exons 2 and 4, 2 and 7, and 7 and 9, respectively, were seen in most of the tumors, three of the four normal prostate samples, and in the pooled RNA from the 62 normal prostate tissues. Figure 3 shows examples of the patterns obtained with primer pairs 195U/864L. All FHIT-speci®c variants observed in a given specimen by nested PCR were also found using the appropriate primer pair. These alternatively spliced transcripts were clearly no more prominent in the tumors than in the normal prostate specimens in keeping with results from Boldog et al. (1997) . The present result con®rms that FHIT variants are present at a far lower level (51%) than the full-length transcript in both normal and neoplastic prostate tissue. As the FHIT open reading frame is contained in exons 5 ± 9 (Figure 1a) , it is unlikely that most of these alternatively spliced transcripts encode functional proteins. The absence of exon 8, which contains the histidine triad domain, is also one of the most frequent variation observed in breast cancer , squamous cell carcinomas of the head and neck (Virgilio et al., 1996) , renal cell carcinomas (Luan et al., 1997) , and also in normal fetal brain cDNA (Boldog et al., 1997) , whereas loss of exon 3, that¯anks the t(3;8) translocation, has been observed in the prostate cancer-derived cell line LNCaP .
Tumor heterogeneity might explain the presence of both normal and abnormal FHIT RT ± PCR products T56  T57  T58  T59  T60  T62  Blank  N1  CLO  N111  N159 M 258 bp Figure 3 Representative results obtained using primer pair 195U/864L (see Materials and methods), which revealed alternative FHIT transcripts generated by the fusion of exon 2 and exon 7. The 258 bp FHIT variant was detected in tumors (T56, T57, T58, T59, T60, T62), normal prostate tissues (N1, N111, N159), and pooled RNA from normal human prostate tissues (CLO). M, lane containing commercial molecular weight marker (éX174 DNA digested with HaeIII). Blank, control run in which reverse transcriptase was omitted in individual tumors. Indeed, our LOH study on prostate tumors using three polymorphic markers which lie within the FHIT gene (D3S1481, D3S1300, and D3S1234) showed that two tumors (T60 and T62) were deleted at the FHIT locus. The relative intensity of the two alleles in these tumor DNAs diered from the relative intensity in lymphocyte DNA by a factor of 1.9. The proportion of tumor cells in T60 and T62 was 90% and 80%, respectively, and the value of 1.9 indicates that LOH at the FHIT locus occurred in 52% of tumor cells in T60 and 59% in T62, suggesting intratumoral heterogeneity. However, the spliced FHIT variants in these two tumors were present at a very low level. Comparison of the results on FHIT variants and those of genomic DNA analysis argues against a correlation between LOH at 3p14.2 and the aberrant transcripts in these two tumors. DNA analysis also suggested that genomic alteration of FHIT does not play a causative role in the aberrant transcripts observed in prostate cancer. Moreover, these alternatively spliced transcripts generated by fusion of dierent exons of the normal FHIT gene sequence were no more prominent in the tumors than in the normal prostate specimens, indicating that tumor heterogeneity is not a likely explanation for presence of normal and abnormal FHIT RT ± PCR products in individual tumors. The use of tumor samples containing more than 60% of tumor cells made it impossible that the normal products derived from contaminating non neoplastic cells, contrary to lung cancer (Sozzi et al., 1996a) , Merkel cell carcinoma (Sozzi et al., 1996b) and head and neck cancer (Virgilio et al., 1996) . In conclusion, our studies clearly show that an intact wild-type transcript, containing the complete FHIT coding region was observed in all normal and malignant prostate specimens studied here. This normal product did not derive from contaminating non neoplastic cells, and was always the major product. Alternatively spliced transcripts, which did not appear to be due to DNA lesions, in the FHIT locus, were coexpressed at a far lower level than the full-length transcript (51%). These aberrant transcripts were also present in normal prostate tissue, and were no more abundant in tumors than in normal prostate. Taken together, these results suggest that aberrant FHIT transcripts were not related to prostate tumorigenesis, but simply re¯ected the plasticity of alternatively splicing. The observed FHIT variants may be due to the fact that the FHIT gene lies within the FRA3B common fragile site, as we had never previously observed such variants in other genes (data not shown).
However, as alterations in translational control, or even altered patterns of Fhit protein expression, may also play a part in tumorigenesis, additional functional studies are required to de®ne the potential role of FHIT in prostate cancer.
Materials and methods
Patients and samples
Fifteen primary prostate tumor specimens were obtained from patients undergoing surgery at St Louis Hospital in Paris, and La Cavale Blanche Hospital in Brest (France). The samples were examined histologically to evaluate the presence of tumor cells. A sample was considered suitable for experiments if the proportion of tumor cells was more than 60%. Peripheral blood leukocytes were used as a source of normal DNA for each patient, and four normal prostate tissue specimens and RNA from a pool of 62 normal human prostate tissues (Clontech) were used as sources of normal RNA.
RNA extraction and RT ± PCR
Total RNA was extracted from prostate samples by using the acid-phenol guanidium method (Chomczynski and Sacchi, 1987) . The quality of the RNA samples was determined by electrophoresis through denaturing agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under ultraviolet light. The yield was quanti®ed spectrophotometrically in a 50 ml microcuve. Reverse transcription was performed in a total volume of 20 ml. Total RNA (1 mg) was reverse-transcribed using random hexamers and MuLV reverse transcriptase according to the protocol supplies with the GeneAmp 1 RNA ± PCR Core kit (Perkin Elmer). One microliter of the reaction mix was used for PCR.
Primers and PCR conditions
Single-stage and nested PCR were carried out in a ®nal volume of 50 ml containing 1 ml of the RT reaction mix, 20 pmoles of each primer, 200 mM each dNTP, 1.5 mM MgCl 2 , 10 mM Tris-HCl pH 8.3, 50 mM KCl and 1 unit of Taq DNA polymerase (Perkin Elmer). Primers are designated by nucleotide position (relative to FHIT Genbank #U49922) corresponding to the 5' position, followed by the letter U for upper (i.e. sense strand) or L for lower (i.e. antisense strand). Single-stage PCR steps, using the primer pair 109U(exon 1)/864L(exon 10) (Figure  1 ), ampli®ed a 756-bp FHIT cDNA product. PCR consisted of an initial denaturation at 948C for 5 min and 30 cycles of 1 min at 948C, 1 min at 628C, and 1.5 min at 728C, and a ®nal extension of 10 min at 728C, using a Perkin-Elmer 9600 DNA thermocycler.
Nested PCR was performed using 109U/864L for the ®rst round of ampli®cation (25 cycles). The ampli®ed products were then diluted 20-fold and 1 ml of the diluted product was then subjected to 30 cycles in the above conditions, using the primer pair 155U(exon 2)/837L(exon 10), nested inside the original primers (Figure 1 ). The expected cDNA product is 683 bp. Single-stage and nested PCR products from each mRNA sample were then separated on 2% agarose gels, and stained with ethidium bromide. To con®rm the presence of alternatively spliced speci®c FHIT transcripts, single-stage PCR ampli®cation of the RT products was carried out for 30 cycles using primer pairs 182U/864L, 195U/864L and 109U/ 726L. The oligonucleotide 182U spans the end of exon 2 and the beginning of exon 4, 195U spans the end of exon 2 and the beginning of exon 7, and 726L spans the beginning of exon 9 and the end of exon 7 (Figure 1) .
The sequences of the oligonucleotides were as follows: 109U: 5'-CCTCCCTCTGCCTTTCATTC-3'; 155U: 5'-GAA GCTCAGGAAAGAAGAGAAATC-3'; 182U: 5'-TGAGAA-CAGTCTGTAAAGGTATCCTA-3'; 195U: 5'-TAAAGGAT GGCCCCGAAG-3'; 726L: 5'-TGTCATGTTTCTGGAGC TTCAC-3'; 837L: 5'-GCTGGAATTCAGGATCTGAAA-3'; 864L: 5'-TTCAAACTGGTTGGCAATAGC-3'.
Quantitative FHIT transcript analysis
The ratio of DNA fragments generated by FHIT transcripts (aberrant/wild-type) was independent of the cycle number. Thus, coampli®cation of all transcripts provided a semiquantitative RT ± PCR method, in which the internal control was the coampli®ed wild-type FHIT mRNA, and comparative expression of abnormal mRNA and wild-type FHIT mRNA could be determined for each sample. Oligonucleotides 109U and 837L were¯uorescein-labeled at their 5' end by adding Fluorprime during oligonucleotide synthesis, and the sensitive Applied Biosystems model 373A DNA sequencing system (Perkin Elmer) was used to detect and quantify the dierent signals. Single-stage and nested PCR products were diluted tenfold and 2.5 ml-aliquots of each were added to 2.5 ml of deionized formamide containing 0.3 ml of a molecular size marker (Genescan 2500 ROX, Perkin Elmer). The mixtures were heat-denatured and 2.5 ml aliquots of each were loaded on 6% polyacrylamide 8-M urea gel and run for 6 h at 1200 V in the sequencer. The dierent fragments were quanti®ed with the Genescan 1 672 Fragment Analysis software (Perkin Elmer), which calculated the size and area of the peaks. The area of each peak for a given cDNA sample was then normalized to the sum of the areas of all the peaks obtained with the same sample.
Sequencing of PCR products
PCR products were resolved in 1.5% low-melting-point agarose gel (BRL) stained with etidium bromide. DNA fragments were cut from gels and puri®ed using the QIAquick PCR puri®cation kit (Qiagen). The puri®ed fragments were sequenced using the Applied Biosystems (ABI) PRISM Dye Terminator Cycle Sequencing kit (Perkin Elmer) on the Applied Biosystems model 373A DNA sequencing system (Perkin Elmer).
DNA analysis
We used the polymorphic markers D13S1481, D3S1300, and D3S1234 which lie within the FHIT gene (intron 3, intron 5 and intron 8, respectively), for LOH analysis. The sequence of the primer pairs were obtained from the Genome DataBase: D13S1481 (GDB ID: , D3S1300 (GDB ID: GOO-188-420), and D3S1234 (GDB ID: GOO-186-387). The PCR reactions were carried out in a total volume of 15 ml containing 50 ng of genomic DNA, 3 pmol of each primer (one¯uorescently labeled), 1 mM each deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 10 mM Tris-HCl pH 8.3, 50 mM KCl and 0.6 units of Taq DNA polymerase. Conditions for ampli®cations were: 948C for 5 min, 12 cycles of 948C for 15 s, 558C for 15 s 728C for 30 s followed by 22 cycles of 898C for 15 s, 558C for 15 s and 728C for 30 s. The ®nal extension step at 728C was extended to 10 min. Products were diluted 20-fold. The procedure which followed is described above (see Quantitative FHIT transcript analysis). Allelic imbalance was considered to be present when the relative intensity of the two alleles in tumor DNA diered from the relative intensity in lymphocyte DNA by a factor of at least 1.5; this is a validated cut-o value to determine AI of microsatellite loci in tumor samples containing 460% cancer cells (McGrogan et al., 1994) . Each analysis was performed at least twice to ensure reproducible detection of AI (repeat independent PCR ampli®cation, gel separation, and quanti®cation). In an attempt to distinguish allelic gain from LOH, comparative multiplex PCR (Cairns et al., 1994) was performed with the microsatellite marker D4S244 or D21S222 (Hudson et al., 1992) located in unaltered chromosomal regions (Watanabe et al., 1995) , as internal controls.
